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Abstract
Background: In November 2016, the ICH published a requirement for sponsors to develop a systematic, prioritised,
risk-based approach to monitoring clinical trials. This approach is more commonly known as risk-based monitoring
(RBM). However, recent evidence suggests that a ‘gold standard’, validated approach to RBM does not exist and it is
unclear how sponsors will introduce RBM into their organisations. A first step needed to inform the implementation
of RBM is to explore academic trialists’ readiness and ability to perform RBM. The aim of this paper is to identify the
attitudes and perceived barriers and facilitators to the implementation of RBM in academic-led clinical trials in
Ireland.
Methods: This is a mixed-methods, explanatory sequential design, with quantitative survey followed by
semistructured interviews. Academic clinical researchers (N = 132) working in Ireland were surveyed to examine
their use and perceptions of RBM. A purposive sample of survey participants (n = 22) were then interviewed to gain
greater insight into the quantitative findings. The survey and interview data were merged to generate a list of
perceived barriers and facilitators to RBM implementation, with suggestions for, and solutions to, these issues.
Results: Survey response rate was 49% (132/273). Thirteen percent (n = 18) of responders were not familiar with the
term risk-based monitoring and less than a quarter of respondents (21%, n = 28) had performed RBM in a clinical
trial. Barriers to RBM implementation included lack of RBM knowledge/training, increased costs caused by greater IT
demands, increased workload for trial staff and lack of evidence to support RBM as an effective monitoring
approach. Facilitators included participants’ legal obligation to perform RBM under the new ICH-GCP guidelines,
availability of RBM guidance and perception of cost savings by performing RBM in future trials.
Conclusion: The results of this study demonstrate a need for training and regulatory-endorsed guidelines to
support the implementation of RBM in academic-led clinical trials. The study provides valuable insights to inform
interventions and strategies by policy-makers and clinical trial regulators to improve RBM uptake.
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Background
In 1996, the International Conference on Harmonisation
(ICH) published the first Good Clinical Practice guide-
lines (GCP) for clinical trial conduct [1]. Under ICH-
GCP, sponsors in America, China and the European
Union are legally obliged to monitor their trial activity
[1]. Monitoring aims to protect the rights and wellbeing
of trial participants, support accurate data collection and
ensure compliance with regulatory requirements [1].
Traditionally, trials were monitored through intensive
on-site monitoring visits with 100% source data verifica-
tion (SDV) [2]. SDV can be a labourious task because it
involves the validation of data presented in Case Report
Forms (CRFs) against original source data, such as Con-
sent Forms, irrespective of the trial’s risk profile [2].
Risks associated with the Investigational Medicinal Prod-
uct (IMP), the vulnerability of the study population and
the robustness of the study design are not considered
when developing a traditional trial monitoring plan [2,
3].
In recent years the scale, complexity and costs of clin-
ical trials have increased beyond the scope of the original
ICH-GCP [4]. In November 2016, the ICH published the
Integrated Addendum to ICH E6 (R1): Guideline for
Good Clinical Practice E6 (R2) to respond to the chan-
ging clinical trial landscape [4]. Under the revised ICH-
GCP guidelines, risk-based monitoring (RBM) is now
mandatory for all trials [4]. RBM incorporates both cen-
tralised monitoring conducted off-site through an exam-
ination of data captured on an electronic data capture
system (EDC) and on-site monitoring practices that are
proportional to the risks associated with the clinical trial
[5]. These risks relate to the Investigational Medicinal
Product (IMP), the study population, research team ex-
pertise and the robustness of the study design [6, 7].
When developing a RBM plan, the trial’s protocol must
be formally assessed to identify risks within the trial that
can be mitigated through either on-site and/or centra-
lised monitoring [8]. Accordingly, risk assessment is the
cornerstone of RBM [9]. The emphasis on RBM is due
to the assumption that it prevents waste of valuable clin-
ical trial resources, such as study budget and staff time,
on unnecessary monitoring activity that does not im-
prove participant safety or data quality [10, 11].
The Organisation for Economic Co-operation and De-
velopment (OECD) recommends that clinical re-
searchers to use a RBM tool when developing a RBM
plan [12]. Such tools have two functions: first they sup-
port the assessment of risk in a clinical trial protocol
and second they provide guidance for subsequent moni-
toring activity (on-site/centralised) that can mitigate the
risk identified [12]. We recently published a systematic
review that identified 24 RBM tools that met the OECD’s
criteria [13]. However, there were many differences
between the tools in terms of mode of administration
(paper-based versus software as a system), the baseline
risk assessment process and guidance for on-site and
centralised monitoring [13]. For example, the Medical
Health Regulatory Authority (MHRA) advise 100% cen-
tralised monitoring for low-risk, phase III trials, while
the Swiss Clinical Trial Organisation (SCTO) advise
both on-site and centralised monitoring for similar low-
risk trials [5, 8].
In the absence of a ‘gold standard’ approach to RBM, it
remains unclear how sponsors will implement it into
their clinical trial units [14]. Given this context, it is im-
portant to establish how prepared academic trialists are
to perform RBM [8]. Presently, Ireland does not have a
national strategy to support the introduction of RBM
into its publicly funded, academic run clinical trial units.
A first step in the development of such a strategy in-
volves the identification of academic trialists’ readiness
and ability to perform RBM [14]. In this study we ex-
plore the experience of, attitudes to, and perceived bar-
riers and facilitators associated with, the implementation
of RBM in academic-led clinical trial units in Ireland.
Methods
Design
We used a mixed-methods, explanatory sequential de-
sign. This design occurs in two distinct but interactive
phases [15]. It begins with the collection and analysis of
quantitative data, followed by qualitative data collection
and analysis to further explore the quantitative results
(see Fig. 1) [15]. In this study, methods were combined
for complementarity, where each method addressed a
different aspect of the research question. The quantita-
tive phase collected numerical data on the uptake of
RBM in Ireland and its associated uses. The quantitative
results facilitated sampling and development of the sub-
sequent qualitative phase which further examined the
barriers and facilitators associated with RBM [16].
Phase 1 – Quantitative surveys
Survey development
The study survey was adapted from the Clinical Trials
Transformation Initiative (CTTI) monitoring question-
naire [17]. The CTTI questionnaire contained 55 ques-
tions, collecting information on institutional
demographics, overall study oversight methods, the use
of risk- based monitoring, factors that influence moni-
toring risk assessments, and details on on-site and cen-
tralised monitoring practices [17].
Our survey is a shortened and modified version of the
CTTI questionnaire. Questions pertaining to a trial’s
governance and verifications performed during on-site
monitoring visits were excluded from our survey as they
were not relevant to the current study. Our study also
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included additional questions on RBM tools which were
not explored in the CTTI survey. In total, our survey
contained 20 questions. These include question regard-
ing the participants’ demographics and their experience
and understanding of the three primary components of
RBM which are (1) risk assessment, (2) on-site monitor-
ing and (3) monitoring. A number of questions focussed
on respondent’s clinical trial experience since the intro-
duction of the European Communities-Clinical Trials on
Medicinal Products for Human Use Regulations to
Ireland in 2004 [18]. The full survey can be found in
Additional file 1.
The survey questions required responses that were ei-
ther yes/no, multiple choice or open ended. Before dis-
tribution, the survey was pilot tested with a sample of 10
clinical researchers and further modification was not
required.
Recruitment
The Health Research Board-Clinical Research Coordin-
ation Ireland (HRB-CRCI) is an independent, integrated,
national clinical research network [19]. It was estab-
lished in 2014 to provide centralised support in the con-
duct of multicentre clinical trials across Ireland [19].
Currently, the HRB-CRCI operates as a collaborative
partnership with five Clinical Research Facilities/Centres
(CRF/Cs) based in five universities across Ireland [19].
Researchers working in the CRF/Cs were eligible to par-
ticipate in the survey. Participants included principle in-
vestigators (PIs), pharmacists, study physicians, nurses,
project and quality managers, study monitors and
biostatisticians.
Data collection
The survey was administered via Survey Monkey, an on-
line Cloud-based survey development software [20]. Par-
ticipants received the survey invitation via an email sent
from the Director of the Clinical Research Facility, Cork.
This email was sent to participants between February
and April 2016. It contained an online link to the survey.
One reminder email was sent to all, 3 to 6 weeks after
the initial email. The online survey was open for 10
Fig. 1 Study design – mixed-methods, explanatory sequential design procedure [15]
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months from February to November 2016. However,
70% of survey responses were collected between Febru-
ary and June 2016.
Data analysis
Data captured in Survey Monkey were downloaded into
Excel and then exported into SPSS version 11 for
analysis.
Phase 2 – Qualitative interviews
Methodology
Thematic analysis was used to identify barriers and facil-
itators to the implementation of RBM in participants’
past, present and future clinical trials [21].
Recruitment
Recruitment took place over 4 weeks from 26 September
to 24 October 2016. Eligible participants were identified
from respondents to the online survey who had an-
swered survey question 8.4, 9.3 or 10.2, ‘Since 2004, have
you implemented a RBM plan in a clinical trial?’ Re-
sponders of question 10 (n = 107) were grouped into
three categories (A, B or C) based on their response;
group A answered ‘Yes’; group B answered ‘No’; and
group C answered, ‘I am not familiar with the term “risk-
based monitoring”’.
Sampling
A purposive sample (n = 24) of different clinical re-
searchers (PIs, nurses, physicians, monitors, pharmacists,
managers, biostatisticians) were selected from group A
(n = 8), group B (n = 8) and group C (n = 8) and invited
to participate in the interviews via an email invitation.
Two participants declined the invitation due to work
commitments.
Setting
Face-to-face or telephone interviews (if the participant
was not available for face-to-face) were conducted by an
independent researcher (CH) from 7 October to 29 No-
vember 2016. Face-to-face interviews were conducted in
a private room in each participant’s work place.
Data collection
A semistructured topic guide was developed to guide
data collection. The topic guide was based on the results
from phase 1. The topic guide included open-ended
questions including: the participant’s most recent clinical
trial experience including how this trial was monitored;
their understanding and attitudes towards RBM; fore-
seen benefits and limitations of RBM; and factors that
would facilitate or hinder them from implementing
RBM in future trials. The topic guide was piloted on
three clinical researchers based in the Clinical Research
Facility, Cork and minor revisions were made. Revisions
involved the inclusion of three questions pertaining to
participants’ past clinical trial monitoring experience.
These questions were included to gain a greater insight
into the participant’s clinical trial experience. The full
topic guide can be viewed in Additional file 2.
All participants received a Patient Information Leaflet
and consent was obtained from all participants for their
interview to be audio-taped and the content to be used
for research purposes. Interviews lasted between 20 and
35 min. Data saturation was reached when additional in-
formation relating to barriers and facilitators to RBM
implementation was no longer obtained from interview
participants [22]. Data saturation was assessed independ-
ently for groups A, B and C. Data saturation was
reached for group A after interview 5, group B after
interview 4 and group C after interview 3. However, all
scheduled interviews were conducted, transcribed and
analysed.
Data analysis
Interviews were audio-recorded and transcribed verba-
tim. Transcribed interviews were coded and analysed by
two coders CH (epidemiologist and clinical trial method-
ologist) and ER (social policy researcher) using the quali-
tative data analysis software NVivo [23]. The analysis
followed the six phases of thematic analysis outlined by
Braun and Clarke which include familiarisation with the
data, generating initial codes, searching for, naming, de-
fining and reviewing themes and producing a report
[21]. The main themes were found after repeated read-
ing of the interview transcripts, paying careful attention
to barriers and facilitators associated with the implemen-
tation of RBM in past, present and future clinical trials.
Barriers were defined as perceived obstacles that would
prevent or impact clinical researchers’ implementation
of RBM [24]. Facilitators were defined as processes that
would support RBM implementation [24]. Emerging
themes were organised hierarchically in three levels of
analysis. At the first level are texts relating to the bar-
riers and facilitators associated with RBM implementa-
tion that were identified across the data set. At the
second level are the subthemes, where different codes
were combined because they shared an underlying
meaning. At the third level are the main barriers and fa-
cilitators associated with the implementation of RBM.
Data integration
The Good Reporting of a Mixed Methods Study
(GRAMMS) framework was used to inform reporting of
the findings [25]. The survey and interview data were in-
tegrated at the data interpretation phase using the
method of merging data [26]. Merging occurs when re-
searchers bring two data bases together for analysis and
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comparison [26, 27]. In this study, the research team
conducted separate analyses of the quantitative survey
data and the qualitative interview data in parallel. Quali-
tative information was used to explore quantitative in-
formation collected in phase 1, as dictated by the
explanatory sequential design [28].
Ethics
The study received ethical approval from the Research
Ethics Committee of the Cork Teaching Hospitals
(CREC). Informed consent was received from all study
participants.
Results
Participant characteristics and RBM uptake
The survey response rate was 49% (132/273). Character-
istics of the survey participants are described in Table 1.
Forty percent of respondents were PIs (n = 53). Most re-
spondents had over 6 years’ experience in working in
clinical trials (57%, n = 76) and over half had conducted
an international multicentre trial (n = 93, 70%).
Survey findings showed that 37% (n = 49) of re-
sponders had conducted RBM since 2004. However, re-
gardless of prior RBM experience, all survey participants
said that the Investigational Medicinal Product (IMP)
under investigation, the phase of the clinical trial and
the experience of the study team were the main factors
that they would use to determine how often a study
monitor needed to visit a trial site to perform on-site
monitoring. Survey responders reported that several
protocol deviations or a high dropout rate would war-
rant additional/triggered on-site monitoring.
In total, 24 survey respondents from four of the five
CRF/Cs were invited to participate in the semistructured
interviews. Twenty-two interviews were conducted (RR
= 92%). Interview participants included PIs (n = 6),
nurses (n = 5), monitors (n = 3), study physicians (n = 3),
quality managers (n = 3), biostatistician (n = 1) and trial
pharmacist (n = 1).
Barriers associated with the implementation of RBM
Lack of knowledge/training
The survey results showed that 14% (n = 18) of re-
sponders were not familiar with the term RBM. Of the
participants who did not conduct a risk assessment in
the most recent clinical trial that they worked on (n =
35), 17% felt that they did not have the expertise to per-
form a risk assessment (Table 2). Over 80% (n = 114) of
survey responders categorised barriers to implementing
centralised monitoring. Almost two thirds of these par-
ticipants (62%, n = 71) identified lack of education as a
very important barrier (Table 3). The interview data con-
firmed that several participants had not used RBM in
past trials because they were not familiar with this type
of monitoring and many did not know that RBM would
be introduced in the new ICH-GCP guidelines:
‘Well, just from talking to yourself, I have to admit,
prior to that I hadn’t heard about this, so I wasn’t aware
that the GCP was going to be changing’ (Study
physician-1).
Several interviewees, who had not conducted RBM in
past trials, felt that they did not have sufficient RBM
training to confidently perform RBM in future trials:
‘It would come down to the practical aspects on how
is risk defined …what information are people using to
make that judgement. How is it actually implemented?
But ultimately I’d have to understand that before I could
say I was happy to do it’ (PI-1).
They did not feel able to classify clinical trial risks and
to translate these risks into monitoring activity. Simi-
larly, some interviewees who had conducted RBM in
past trials still felt ill-equipped to perform RBM in their
future trials:
‘We would say we have conducted a type of risk-based
monitoring, but it’s getting to the actual nitty-gritty of
exactly what fields you’re going to look at and exactly
what parameters are in those fields. I would say that I’d
be still a bit unsure of that’ (Nurse-1).
Table 1 Online survey participants’ characteristics and use of
clinical trial monitoring
Variable Total (n = 132) %
Participants – clinical trial role
Principal investigator (PI) 54 41%
Clinical trial nurse 35 26%
Project manager 21 16%
Quality manager 4 3%
Study physician 5 4%
Study monitor 5 4%
Biostatistics 2 1%
Pharmacists 6 5%
Number of participants who have conducted the following type of trial
Industry-/commercial-led, regulated clinical trial 99 75%
Academic-led, regulated clinical trial 104 78%
Non-regulated clinical trial 79 60%
Clinical trial experience (years)
< 1 5 4%
1–3 37 28%
4–6 14 11%
> 6 76 57%
Conducted an international multicentre clinical trial
Yes 93 70%
No 39 30%
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Survey responders reported having limited experience
of using centralised monitoring for essential monitoring
activity such as assessing protocol compliance, inspect-
ing informed consent and recording pharmacovigilance
information. Lack of education was the main reason that
survey participants did not perform centralised monitor-
ing (Table 3). A small number of participants from the
five CRF/Cs (n = 17) reported having a Standard Operat-
ing Procedure (SOP) for centralised monitoring in their
CRF/C. However, over a third of participants (n = 48)
were unsure if such a SOP existed in their CRF/C. Ana-
lysis of the qualitative interviews showed that some
study nurses and monitors did not know how centralised
monitoring could replace on-site monitoring. One par-
ticipant felt that on-site monitoring offered better gov-
ernance of junior clinical trial staff. This participant felt
that centralised monitoring would result in monitors
having less oversight of clinical trial activity:
‘As sponsor, all of the monitoring is on-site, and that’s
for two reasons…, because it’s our first time working
with a lot of these investigators and we’re not sure of
their experience in running regulated trials, we want to
make sure that they understand what’s required and
what they need to do in terms of quality’ (Monitor-2).
Increased cost caused by greater Information Technology
(IT) demands
Almost half the survey responders identified IT demands
(46%, n = 53) and cost (40%, n = 45) as problems associ-
ated with the implementation of centralised monitoring
in past and future clinical trials (Table 3). The interview
data revealed that this perception was related to higher
costs associated with EDC systems. Some interviewees
felt that centralised monitoring would be costly to run
as they would have to store trial data on an EDC system:
‘As sponsor, all of the monitoring is on-site…, because
we don’t have electronic data capture in any of these
studies because they’re not commercial studies – they’re
usually grant funded, or just the PI – so there’s very little
money, you’re using paper CRF’.(Monitor-1).
This was a particular concern for trialists working on
smaller trials. They felt that they would not have suffi-
cient budget to support an EDC system and were only
resourced to conduct on-site monitoring:
‘Some of the eCRFs, let’s say that company that we
had, you could be talking nearly half a million, a million
to get it up and running, and what small study has that
if you’re talking about an oncology study which has
maybe 10 patients coming into it? An eCRF is not going
to be worth the set-up costs. So they’ll stick to the paper’
(Monitor-3).
Increased work load
Survey findings showed that perceived work load was
the main reason why responders did not conduct a risk
assessment prior to developing the monitoring plan for
their most recent trial (Table 2). Forty-one percent of
survey responders (n = 114) thought that increased
workload was a barrier associated with the implementa-
tion of centralised monitoring (Table 3). Interviewees,
who had previously conducted centralised monitoring,
felt that it resulted in more administration work for trial
sites as they had to support trial monitors by scanning
and uploading site documents to EDC systems:
‘I noticed one of the girls downstairs was saying in the
last couple of weeks… this company kept saying, “We
still don’t have the CV,” and she’d sent it three times to
Table 2 Reasons why survey responders did or did not conduct a risk assessment prior to developing the monitoring plan
Participants who did conduct a risk assessment (n = 50) % Participants who did not conduct a risk assessment (n = 35) %
Facilitators Barriers
To improve patient safety 43 (86%) Question not relevant, developing monitoring plan is a sponsor duty 15 (43%)
To improve data accuracy 32 (64%) It is not a GCP requirement 7 (20%)
To fulfil GCP requirements 29 (58%) Do not have the expertise to perform a risk assessment 6 (17%)
To determine a schedule for on-site monitoring visits 21 (42%) It is too time consuming 6 (17%)
To fulfil HPRA/IMB requirements 20 (40%) It will not improve patient safety 2 (6%)
To reduce monitoring costs 8 (16%) It is too expensive 1 (3%)
GCP Good Clinical Practice, HPRA Health Protection Regulatory Authorities, IMB Irish Medicines Board
Table 3 Perceived problems associated with the implementation of centralised monitoring (n = 114)
Factor Very important Moderately important Not important
Lack of education and training in centralised monitoring 71 (62%) 36 (31%) 8 (7%)
Cost associated with centralised monitoring 45 (40%) 54 (48%) 13 (12%)
Information Technology (IT) demands of centralised monitoring 53 (46%) 53 (46%) 9 (8%)
Workload associated with centralised monitoring 47 (41%) 48 (16%) 18 (16%)
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them. So you need to have good people at the other side
doing the monitoring and stuff like that. It’s just if it’s
maybe stuff from the trial master file that they’re not
here checking and consent forms and that. That prob-
ably might add some work’ (Nurse-3).
Some interview participants felt that sponsors would
use RBM as an excuse to perform less on-site monitor-
ing and more remote monitoring. These participants felt
that a reduction in on-site visits would results in a trial
monitors spending less time on site checking trial docu-
mentation such as patient Consent Forms. These partici-
pants felt that study nurses may be expected to do extra
administration tasks to support trial monitors perform
remote monitoring:
‘They have these centralised systems now where every-
thing is stored centrally and it’s, like, “Logon and you’ll
find the latest version of your protocol”. So you have to
complete training for that system, you have to logon
every time the new protocol is available or whatever.
The onus is on the site to print it off. The onus is on the
site to do everything and it’s just more and more it’s on
the site, and we are not paid adequately for everything
that we are being requested to do. It’s our admin staff as
well. It’s like they’re just working for the pharma com-
panies. There’s just a huge amount of resources, and it’s
not accounted for’ (Nurse-4).
Lack of verification
The survey found that 27% (n = 35) of responders did
not conduct a risk assessment prior to developing the
monitoring plan for their most recent clinical trial. Some
participants did not conduct a risk assessment because
they felt that it was not a GCP requirement and would
not improve patient safety (Table 2). However, these par-
ticipants did use an informal process to determine what
level of on-site monitoring was required for their clinical
trial. Also, 21% of survey responders (n = 28) reported
previous RBM experience.
Interview analysis showed that participants perceived a
lack of scientific evidence supporting RBM and saw this
as a potential barrier to its implementation in their fu-
ture clinical trials. Many felt that sufficient proof did not
exist to confirm that RBM was at least as effective and
efficient as the 100% SDV on-site monitoring process
that they currently used:
‘So it’s just our experience that the more frequent the
monitoring the better. I have a negative attitude towards
already a negative perception of the risk-based monitor-
ing because 100% source data verification is what I
would prefer’ (Nurse-1).
Some interviewees believed that RBM would lead to a
greater reliance on centralised monitoring and a move
away from on-site monitoring:
‘I know the new ICH-GCP guidelines are more into
the technology, and I know that’s the way we’re going
and things like that. At the end of the day, I don’t think
it fully replaces the on-site’ (Nurse-2).
Many felt that the merits of centralised monitoring
had yet to be proven and so were not comfortable con-
ducting RBM in future trials if it meant fewer on-site
visits:
‘I suppose the fact that things are going more elec-
tronic and it is more EDC-based. It’s the management of
stuff that cannot be converted into EDC and how that’s
going to be verified and how that’s going to be moni-
tored’ (Monitor-1).
Facilitators
Necessary requirement/mandate
Compliance with GCP was the main criterion partici-
pants considered when selecting a RBM tool. Of the 35
survey responders who did not conduct a risk assess-
ment of their most recent monitoring, 20% (n = 7) of
these participants attributed this to the absence of a
GCP requirement to do so (Table 2). Correspondingly,
the interview data confirmed that fulfilling GCP require-
ments would now motivate them to conduct RBM in fu-
ture trials:
‘Yes, we will because it will be ICH-GCP will require
us to do so’ (Monitor-3).
A number of interview participants said that adapting
monitoring to the level of risk was a justified addition to
ICH-GCP:
‘It does make sense that there’s some degree difference
of risk, and therefore that the regulator environment
would recognise that’ (PI-2).
They viewed the new requirements positively because
they felt that RBM was a more sustainable approach to
monitoring than existing approaches:
‘The landscape of clinical research has been changing,
and is always changing, and just changes, changes… It is
inevitable because the days of 100% source data verifica-
tion is just not sustainable, really. But yeah, no, we’re
definitely going to go down that route, so we are, when
we get ourselves together. You know, we get more expe-
rienced, and get a bit of training’ (PI-4).
Similarly, several participants said that they would im-
plement RBM if it became a funding or publication
requirement:
‘People will put it into practice if it helps them to get
funded or it helps them to publish their work’ (Biostatis-
tician-1).
Availability of, and need for, guidance
Survey results suggest that more regulatory guidance
would have facilitated the use of RBM in past trials
(Table 2). Similarly, most interview participants believed
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that the introduction of regulatory-endorsed guidelines
would facilitate the implementation of RBM. In Ireland,
clinical trials are regulated by the Health Protection
Regulatory Authorities (HPRA) and some participants
suggested that this organisation should lead the way in
RBM implementation:
‘I think it would be very important to have the HPRA
involved, because, as you know, they come and monitor
our studies’ (Monitor-3).
‘Well, somebody from the HPRA. There need to be
quality and regulatory affairs. Managers involved and
stuff like that. HPRA maybe’ (Nurse-5).
Some participants thought that RBM would result in
more efficient monitoring because monitoring activity
would be based solely on the risk classification of each
individual trial:
‘I think it would be useful in making sure that wastage
saved, that there was proper scrutiny of patients in the
study. It’s a robust means of recording data, and prob-
ably having expert, external review of any adverse events’
(PI-5).
Economic benefits
Perceived financial benefit of RBM served as another fa-
cilitator encouraging interview participants to perform
RBM in their future trials. Participants felt that RBM
could reduce trial expenditure because monitoring activ-
ity would only be done as required:
‘But I think it is more cost-effective as well and I think
that is an advantage’ (Quality manager-1).
Some interviewees believed that RBM would lead to a
reduction in the number of on-site visits that would be
performed by a monitor in each trial. These participants
thought that reduced on-site monitoring visits would
lead to an overall reduction in trial expenditure on
monitoring:
‘So there clearly are benefits. The first one is to the ex-
tent that you’re able to replace on-site monitoring with
risk-based monitoring. You have achieved a cost saving
for the sponsor of the study’ (Nurse-5).
Discussion
As far as we are aware, this is the first mixed-methods
study to investigate the perceived barriers and facilitators
to RBM in academic-led clinical trials. Our survey
showed that over one third of respondents had previ-
ously performed RBM. The ICH-GCP Integrated Adden-
dum will come into effect on 14 June 2017 so that that
the proportion performing RBM is likely to rise in the
future. However, the survey results show that currently
the majority of staff in academic CRF/Cs have no experi-
ence of performing RBM. Our qualitative analysis found
a lack of RBM verification as one of the main barriers
preventing interview participants from performing RBM.
Most interviewees said that they would feel uncomfort-
able conducting RBM as they believed its effectiveness
had yet to be proven. Some participants felt that RBM
may reduce the quality of clinical trial monitoring by of-
fering a less intensive monitoring approach compared to
traditional 100% on-site SDV. These concerns are well
founded as scientific evidence confirming the effective-
ness and efficiency of RBM is sparse [29]. To date, re-
sults from the OPTIMON trial are the only ones that
compare RBM to traditional 100% on-site SDV monitor-
ing. Of note, this study lacked sufficient statistical power
to demonstrate non-inferiority of the RBM approach at
detecting errors in the participant consent process, noti-
fication of serious adverse events (SAEs) and incorrect
application of participant’s eligibility criteria [30]. Thus,
data supporting the safety and effectiveness of RBM are
much needed [31]. However, irrespective of this evidence
gap, to be ICH-GCP-compliant clinical researchers must
implement RBM in their future trials [31, 32].
Our study highlighted three additional barriers that
may inhibit the introduction of RBM into academic-led
clinical trial units. These included lack of RBM know-
ledge/training, perceived risk of increased costs caused
by greater IT demands and perceived risk of increased
workload for trial staff. Lack of RBM knowledge/training
was identified as a major obstacle to RBM implementa-
tion among interview participants. Many felt ill-
equipped to perform the initial risk assessment phase of
the RBM process. This finding was reflected in the sur-
vey results, which revealed that less than one third of re-
sponders had performed a risk assessment prior to
developing the monitoring plan for their most recent
clinical trial. Also, the use of risk assessment among our
study population was much lower than the 87% uptake
recorded among American academic clinical trialists in
2011 [17]. The low uptake of risk assessment among our
study participants is a cause for concern. Under the new
ICH-GCP guidelines, sponsors must base their monitor-
ing plans on the results of a risk assessment of their trial
protocol [33]. Therefore, in Ireland, the knowledge gap
surrounding risk assessment must be addressed if aca-
demic trialists are to become proficient RBM practi-
tioners [31]. Interviewees believed that the availability of
regulatory-endorsed guidelines would facilitate the intro-
duction of RBM into their academic-led clinical trial or-
ganisations. To increase the use of risk assessments,
Irish clinical trial regulators should develop or select an
approved RBM tool at a national level [8]. A RBM tool
would provide formal instruction on how to perform a
risk assessment of a clinical trial protocol [12]. Clinical
trial regulators in the United Kingdom and France have
already developed their own RBM tools [5, 7]. Addition-
ally, in 2014, Switzerland became the first European
country to introduce a regulation adopting risk-based
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categorisation into their clinical trial methodology [31].
Consequently, a new article added to the Swiss Federal
Constitution, provided the legal framework to regulate
human research according to the risk to which partici-
pants are exposed [31]. However, it must be noted that
in Switzerland the structured risk categorisation ap-
proach was not better than an ad-hoc risk assessment
approach [31]. Therefore, a RBM tool should only be
used to guide risk assessment and not as a one-size-fits-
all approach.
Survey findings suggest that participants are not yet
equipped to perform centralised monitoring. Participants
had limited experience of performing essential monitor-
ing activity, such as inspecting informed consent and
protocol compliance, through centralised monitoring.
This is worrying as centralised monitoring is a primary
component of RBM. As outlined in the new ICH-GCP
guidelines, sponsors should use centralised monitoring
to complement and reduce the extent and/or frequency
of on-site monitoring [4]. The perception of centralised
monitoring was explored further in the qualitative phase
of this study. Interview analysis showed that some par-
ticipants believed that centralised monitoring would be
costly to run as they would have to store trial data on an
EDC system. Participants who worked on small aca-
demic trials thought that they would have insufficient
budgets to support an EDC system and so they could
only conduct on-site monitoring. The practical chal-
lenges associated with centralised monitoring will impact
the implementation of RBM [9, 34] because centralised
monitoring is a major component of RBM [9]. If re-
searchers do not have the resources to perform centra-
lised monitoring, then in turn they will not be able to
perform RBM as their only option is to mitigate every
clinical trial risk through on-site monitoring. Research is
needed to develop pragmatic solutions to the challenges
surrounding the use of centralised monitoring [35]. In
2016, the Food and Drug Administration (FDA) signed
an Agreement with CluePoints to explore and develop a
data-driven centralised monitoring approach in clinical
trials [36]. CluePoints is an IT company that offers
Cloud-based RBM software. Following the FDA lead, it
may be useful for other countries to develop a national
SOP for centralised monitoring [36]. This may involve
collaboration between academic clinical researchers and
computer programmers who specialise in RBM systems.
Conclusion
The results of this study confirm the absence of, and the
need for, training and the availability of regulatory-
endorsed guidelines to support the implementation of
RBM in academic-led clinical trials. The results of this
study should be used to inform interventions and
strategies by policy-makers and clinical trial regulators
to improve RBM uptake.
Strengths/limitations
To our knowledge, this is the first mixed-methods study
to focus specifically on the barriers and facilitators asso-
ciated with clinical researcher’s implementation of RBM
in academic-led clinical trials. The triangulation of the
data enabled the in-depth examination of our findings,
providing a deeper understanding of the influences at
work and corroborating the interpretation of the data.
This approach improves the validity of the data and in-
creases its comprehensiveness [28]. In addition our study
was reported in accordance with Good Reporting of a
Mixed Methods Study (GRAMMS) framework [25].
We believe that the results of this study are generalis-
able to the global academic clinical trial community that
operates under ICH-GCP guidelines. Our study included
a sample of all researchers who would typically work on
a clinical trial in an academic setting. These include PIs,
nurses, physicians, monitors, pharmacists, managers and
biostatisticians [4]. Our diverse study population allowed
for the collection of data from all types of clinical trial
staff and this increased our understanding of how RBM
will be implemented into a real clinical trial setting [29].
However, our study does have some limitations. The
study used a mixed-methods, explanatory sequential de-
sign, with a quantitative and qualitative component. This
type of study is inherently more challenging than a
single-method study design as it involves the design,
conduct and data integration of two different sources
[37]. Achieving true integration in a mixed-methods
study can be difficult [37]. To overcome this barrier, our
study used the process of ‘merging’ to accurately link
and analyse the quantitative and qualitative data [27]. In-
tegration through merging of data occurs when re-
searchers bring the two databases together for analysis
and for comparison [27]. In the design phase, a plan was
developed for collecting the quantitative and qualitative
data that was conducive to merging the databases [27].
The quantitative survey contained a series of questions
pertaining to RBM that was similar to the questions in-
cluded in the semistructured interviews. The study was
also cross-sectional which meant that estimates of RBM
implementation could only be assessed at the present
time point [38].
It should also be noted that our study was conducted
before the new ICH-GCP guidelines come into effect on
14 June 2017 [32]. A longitudinal study would allow us
to track RBM uptake over time and explore its impact
on clinical trial conduct and monitoring outcomes. Such
a study could use the quantitative results of this study as
baseline data. The response rate for the survey was 49%
and, therefore, responses may represent a biased sample
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and may not be fully representative of all academic clin-
ical researchers working in Irish CRF/Cs. Furthermore,
the response rate for the qualitative phase of our study
was 92%. The high response rate may be due to sam-
pling bias [39]. Finally, the qualitative phase of our study
used two forms of data collection, face-to-face interviews
and telephone interviews. We are confident that this did
not impact the qualitative findings as there were no dif-
ferences apparent in the data generated by both collec-
tion methods. This observation is in line with other
research which found no significant differences in the
data generated by face-to-face and telephone interviews
[40].
Additional files
Additional file 1: Full monitoring survey. (DOCX 744 kb)
Additional file 2: Interview Topic Guide. (PDF 342 kb)
Acknowledgements
Not applicable
Funding
Funding for this research was provided by the Health Research Board-Trials
Methodology Research Network (HRB-TMRN), National University of Ireland,
Galway, Ireland
Availability of data and materials
Not applicable
Authors’ contributions
All authors contributed to the development of the study design, data
collection and analysis, and write-up of the final manuscript. All authors read
and approved the final manuscript.
Ethics approval and consent to participate
The study received ethical approval from the Research Ethics Committee of
the Cork Teaching Hospitals (CREC). Informed consent was received from all
study participants.
Consent for publication
All participants consenting to their data being used for publication purposes.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Health Research Board-Trials Methodology Research Network (HRB-TMRN),
National University of Ireland, Galway, Ireland. 2Department of Public Health
and Primary Care, School of Clinical Medicine, University of Cambridge,
Cambridge, UK. 3Centre for Public Health, Queen’s University Belfast, Belfast,
Ireland. 4Department Epidemiology and Public Health, University College
Cork, Cork, Ireland. 5Health Research Board – Clinical Research Facility,
University College Cork, Cork, Ireland.
Received: 29 May 2017 Accepted: 14 August 2017
References
1. International Conference on Harmonization of Technical Requirements for
Registration of Pharmaceuticals for Human Use. ICH Harmonized Tripartite-
Guideline for Good Clinical Practice – E6(R1); 1996. https://www.ich.org/
fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_
Guideline.pdf
2. Smith CT, Stocken DD, Dunn J, Cox T, Ghaneh P, Cunningham D, et al. The
value of source data verification in a cancer clinical trial. PLoS One. 2012;
7(12):e51623.
3. Ven K, Mannaert H. Challenges and strategies in the use of open source
software by independent software vendors. Inf Softw Technol. 2008;50(9):
991–1002.
4. International Council for Harmonisation of Technical Requirements for
Pharmaceuticals for Human Use (ICH). Integrated Addendum to ICH E6(R1):
Guideline for Good Clinical Practice E6(R2). 2016. Available from: http://
www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/
E6/E6_R2__Step_4.pdf. Accessed on Feb 2017.
5. MRC/DH/MHRA Joint Project. Risk-adapted approaches to the management
of clinical trials of Investigational Medicinal Products. 2011. Available from:
https://www.gov.uk/government/uploads/system/uploads/attachment_
data/file/343677/Risk-adapted_approaches_to_the_management_of_
clinical_trials_of_investigational_medicinal_products.pdf. Accessed on 24
Mar 2016.
6. Journot VPJ, Gaultier C, Daurat V, Bouxin-Métro A, Giraudeau B, Preux PM,
Tréluyer JM, Chevret S, Plättner V, Thalamas C, Clisant S, Ravaud P, Chêne G.
Optimon Collaborative Group. Validation of a risk-assessment scale and a
risk-adapted monitoring plan for academic clinical research studies—the
Pre-Optimon study. Contemp Clin Trials. 2011;32(1):16–24.
7. Brosteanu OHP, Ihrig K, Ohmann C, Paulus U, Pfistner B, Schwarz G, Strenge-
Hesse A, Zettelmeyer U. Risk analysis and risk adapted on-site monitoring in
noncommercial clinical trials. Clin Trials. 2009;6(6):585–96.
8. Swiss Clinical Trial Organisation (SCTO). Guideline for Good Operational Practice –
Version 2.0. 2015. Available from: https://www.scto.ch/dam/jcr:255dc355-69ec-4b5f-
b8b9-9426d231727c/Guidelines%20for%20Good%20Operational%20Practice_V2.0.
pdf. Accessed on Apr 2016.
9. TransCelerate Biopharma Inc. Risk-based Monitoring Methodology Position
Paper—RACT Tool. 2014. Available from: http://www.pdfpublications.com/
xls/the-risk-assessment-categorization-ract-tool-1449522.html. Accessed on
30 Mar 2016.
10. Shukla BK, Khan MS, Nayak V. Barriers, adoption, technology, impact and
benefits of risk based monitoring. Int J Clin Trials. 2016;3(1):9–14.
11. Baigent C, Harrell FE, Buyse M, Emberson JR, Altman DG. Ensuring trial
validity by data quality assurance and diversification of monitoring
methods. Clin Trials. 2008;5(1):49–55.
12. Organisation for Economic Co-operation and Development (OECD). OECD
recommendation on the governance of clinical trials. 2013. [cited 2013
March 20]. Accessed on 20 Mar 2013.
13. Hurley C, Shiely F, Power J, Clarke M, Eustace JA, Flanagan E, et al. Risk
based monitoring (RBM) tools for clinical trials: a systematic review.
Contemp Clin Trials. 2016;51:15–27.
14. Patkar S, Dalal J. Challenges to the implementation of risk-based
monitoring. Clin Res. 2016;30(3):57–60.
15. Ivankova NV, Creswell JW, Stick SL. Using mixed-methods sequential
explanatory design: from theory to practice. Field Methods. 2006;18(1):3–20.
16. O’Cathain A, Murphy E, Nicholl J. Why, and how, mixed methods research is
undertaken in health services research in England: a mixed methods study.
BMC Health Serv Res. 2007;7(1):85.
17. Morrison BW, Cochran CJ, White JG, Harley J, Kleppinger CF, Liu A, et al.
Monitoring the quality of conduct of clinical trials: a survey of current
practices. Clin Trials. 2011;8(3):342–9.
18. Lemaire F, Bion J, Blanco J, Damas P, Druml C, Falke K, et al. The European
Union Directive on Clinical Research: present status of implementation in
EU member states’ legislations with regard to the incompetent patient.
Intensive Care Med. 2005;31(3):476–9.
19. Health Research Board-Clinical Research Coordination Ireland (HRB-CRCI).
Clinical Research Facilities/Centres. 2017. Available from: https://www.hrb-
crci.ie/clinical-research-facilities-centres/. Accessed June 2017.
Hurley et al. Trials  (2017) 18:423 Page 10 of 11
20. SurveyMonkey. SurveyMonkey: free online survey software and
questionnaire tool. 2016. Available from: https://www.surveymonkey.com/.
Accessed Aug 2016.
21. Clarke V, Braun V. Thematic analysis. Encyclopedia of critical psychology.
New York: Springer; 2014. p. 1947–52.
22. Guest G, Bunce A, Johnson L. How many interviews are enough? An
experiment with data saturation and variability. Field Methods. 2006;18(1):
59–82.
23. Castleberry A. NVivo 10 [software program]. Version 10. QSR International;
2012. Am J Pharm Educ. 2014;78(1):25. https://www.ncbi.nlm.nih.gov/pmc/
articles/PMC3930250/.
24. Kincaid D, Childs K, Blase KA, Wallace F. Identifying barriers and facilitators in
implementing schoolwide positive behavior support. J Posit Behav Interv.
2007;9(3):174–84.
25. Cameron RA, Trudy D, Scott R, Ezaz A, Aswini S. Lessons from the field:
applying the Good Reporting of A Mixed Methods Study (GRAMMS)
framework. Electron J Bus Res Methods. 2013;11(2):58-59.
26. Driscoll DL, Appiah-Yeboah A, Salib P, Rupert DJ. Merging qualitative and
quantitative data in mixed methods research: how to and why not.
Ecological and Environmental Anthropology. 2007;3(1).
27. Fetters MD, Curry LA, Creswell JW. Achieving integration in mixed methods
designs—principles and practices. Health Serv Res. 2013;48(6pt2):2134–56.
28. Creswell JW. Research design: qualitative, quantitative, and mixed methods
approaches. SAGE; 2013. https://books.google.com.ph/books/about/
Research_Design.html?id=4uB76IC_pOQC&redir_esc=y.
29. von Niederhäusern B, Orleth A, Schädelin S, Rawi N, Velkopolszky M,
Becherer C, et al. Generating evidence on a risk-based monitoring approach
in the academic setting–lessons learned. BMC Med Res Methodol. 2017;
17(1):26.
30. Journot V. OPTIMON—first results of the French trial on optimisation of
monitoring. 2015. Available from: https://ssl2.isped.u-bordeaux2.fr/
OPTIMON/docs/Communications/2015-Montpellier/OPTIMON%20-
%20EpiClin%20Montpellier%202015-05-20%20EN.pdf. Accessed June 2017.
31. Cevallos M, Züllig S, Christen A, Meier BE, Goetz M, Coslovsky M, et al. A
pilot test of the new Swiss regulatory procedure for categorizing clinical
trials by risk: a randomized controlled trial. Clin Trials. 2015;12(6):677-87.
https://www.ncbi.nlm.nih.gov/pubmed/26122923.
32. European Medicines Agency (EMA). Guideline for good clinical practice
E6(R2). 2016. Available from: http://www.ema.europa.eu/docs/en_GB/
document_library/Scientific_guideline/2009/09/WC500002874.pdf. Accessed
June 2017.
33. International Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use. Integrated Addendum to
ICH E6 (R1): Guideline for Good Clinical Practice. 2015. Available from: http://
www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/
E6/E6_R2__Addendum_Step2.pdf. Accessed on 23 Feb 2016.
34. Cyntegrity. Process Innovation in Clinical Trial Monitoring—PUEKS Project.
2016. Available from: https://cyntegrity.com/publications-projects/pueks/.
Accessed June 2017.
35. Bakobaki JM, Rauchenberger M, Joffe N, McCormack S, Stenning S, Meredith
S. The potential for central monitoring techniques to replace on-site
monitoring: findings from an international multi-centre clinical trial. Clin
Trials. 2012;9(2):257–64.
36. CluePoints. FDA signs agreement with CluePoints to explore a data-driven
approach to quality oversight in clinical trials. 2016.
37. Hadi MA, Closs SJ. Applications of mixed-methods methodology in clinical
pharmacy research. Int J Clin Pharm. 2016;38(3):635–40.
38. Levin KA. Study design III: cross-sectional studies. Evid Based Dent. 2006;7(1):
24–5.
39. Collier D, Mahoney J. Insights and pitfalls: selection bias in qualitative
research. World Polit. 1996;49(01):56–91.
40. Sturges JE, Hanrahan KJ. Comparing telephone and face-to-face qualitative
interviewing: a research note. Qual Res. 2004;4(1):107–18.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Hurley et al. Trials  (2017) 18:423 Page 11 of 11
